Dublin, March 06, 2018 (GLOBE NEWSWIRE) -- The "Microbubbles/Ultrasound Contrast Agents Market - Global Opportunity Analysis and Industry Forecast (2018-2024)" report has been added to ResearchAndMarkets.com's offering.
Global Microbubbles/Ultrasound Contrast Agents Market is expected to reach USD 1,584.5 million by 2024, at a CAGR of 25.2% during the forecast period of 2018 to 2024.
Succeeding an extensive secondary and primary research on microbubbles/ultrasound contrast agents and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, and trends in the market dynamics segment.
Advancement in ultrasound technologies, benefits over alternative technologies, favorable reimbursement policies for contrast enhanced procedures in the U.S., increase in demand for diagnostics & image guided procedures, and growing aging population and subsequent rise in the prevalence of chronic diseases are majorly driving the microbubbles/ultrasound contrast agents market. However, factors such as complexity involved in conducting contrast enhanced ultrasound (CEUS) procedures retard the growth of this market.
In addition, the report further gives an extensive outlook on microbubbles/ultrasound contrast agents market with respect to various therapeutic areas and applications. An in-depth analysis of the geographic scenario of the industry provides detailed qualitative and quantitative insights for the major geographies (North America, Europe, Asia-Pacific, and rest of the World). The geographic analysis provides detailed insights on the key trends of the industry in the listed regions, identifying the demographic & economic impact, and government & private investments. The report identifies North America to be the largest market followed by Europe, Asia Pacific, and Rest of World. The geographic analysis section also comments on the key market players shaping the growth of the industry in the respective regions.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2017).
The key players in the global microbubbles/ultrasound contrast agents market are Lantheus Holdings, Inc., Bracco, GE Healthcare, Daiichi Sankyo Company, Limited, and nanoPET Pharma GmbH.
Key Topics Covered:
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Advancement in Ultrasound Technologies
4.2.1.1.1. Evolution of Microbubbles
4.2.1.1.2. Miniaturization of Ultrasound Devices
4.2.1.1.2.1. Wearable Ultrasound Pain therapy Device
4.2.1.1.2.2. Flow Focusing Microfluidic Devices (FFMDs)
4.2.1.1.2.3. Handheld Ultrasound Scanners
4.2.1.1.2.4. Phone-Based Ultrasound Systems
4.2.1.2. Benefits over Alternative Technologies
4.2.1.3. Favorable Reimbursement Policies for Ultrasound Contrast Enhanced Procedures in the U.S.
4.2.1.4. Increase in Demand for Diagnostics & Image Guided Procedures influencing the Sales of Microbubbles
4.2.1.5. Growing Aging Population and Subsequent Rise in the Prevalence of Chronic Diseases
4.2.2. Restraints
4.2.2.1. Complexity involved in Conducting Contrast Enhanced Ultrasound (CEUS) Procedures
4.2.3. Opportunities
4.2.3.1. Rising Microbubbles/ Ultrasound Contrast Agents Related Research
4.2.4. Trends
4.2.4.1. Expansion- A Key Growth Strategy Adopted by Market Players
5. Microbubbles/Ultrasound Contrast Agents Market, by Therapeutic Area
5.1. Introduction
5.2. Cardiovascular Diseases
5.2.1. Drivers
5.2.1.1. High incidence of Stroke Worldwide
5.2.1.2. Improvisation in therapies to Boost the Application in Sonothrombolysis
5.2.2. Sonothrombolysis: Future Potential
5.2.2.1. Prospects: Targeted Microbubbles
5.2.2.2. Prospects: Gene Delivery
5.3. Renal and Associated Diseases
5.3.1. Ultrasound Applications in Kidney
5.3.1.1. Diagnosis between Solid Renal Masses and Pseudo-Tumors
5.3.1.2. Differentiation between Cystic and Solid Lesions of the Kidneys
5.3.1.3. Characterization of Complex Cystic Renal Masses
5.3.1.4. Renal infections
5.3.1.5. Renal Trauma
5.3.1.6. Renal Artery Stenosis
5.3.1.7. Assessment of Percutaneous Ablation therapy
5.3.1.8. Kidney Transplantation
5.3.1.9. Kidney Fibrosis
5.3.2. Drivers
5.3.2.1. Regulatory Changes and Government Support to Boost Clinical Research Related to Kidney
5.3.3. Restraints
5.3.3.1. Retention of Microbubbles
5.4. Other Diseases
6. Microbubbles/Ultrasound Contrast Agents Market, by Application
6.1. Introduction
6.2. Molecular Imaging
6.2.1. Applications
6.2.2. Trends
6.2.2.1. Development of Novel Microbubbles to Improve Target Binding
6.2.2.2. Development of Novel Microbubbles to Suit the Modalities Used in Imaging
6.2.3. Challenges
6.2.3.1. Currently Ultrasound Molecular Imaging Is Still in Its infancy and Some Challenges Exist
6.3. Gene therapy
6.3.1. Drivers
6.3.2. Methods of Gene therapy
6.4. Drug Delivery
6.4.1. Drivers
6.4.1.1. Growing Number of Researchers in the Field of Drug Delivery Using Microbubbles
6.4.1.2. Rising incidence & Mortality of Cancer & Cardiac Disease to Create Need for Better Drug therapies
6.4.1.3. Growing Researches involving Targeted Drug Delivery Using Microbubbles
6.5. Stem Cell Delivery
6.5.1. Growing Researches
7. Microbubbles/Ultrasound Contrast Agents Market, by Geography
8. Competitive Landscape
8.1. Introduction
8.2. Approvals
8.3. Partnerships, Agreements, and Collaborations
8.4. Expansions & Others
9. Company Profiles
- Lantheus Holdings Inc.
- Bracco
- GE Healthcare
- Daiichi Sankyo Company Limited
- NanoPET Pharma GmbH
For more information about this report visit https://www.researchandmarkets.com/research/rh77ps/global?w=12